Терапевтические средства при аппаратной перфузии донорских органов

Актуальность. Неудовлетворенная потребность в трансплантологической помощи диктует необходимость использования органов от субоптимальных доноров. Аппаратная перфузия, активно развивающаяся в настоящее время, призвана решить данную проблему. В работе рассмотрены современные технологии аппаратной перфузии донорских органов ex vivo и in vivo, которые позволяют улучшить их функции и выполнить успешную пересадку. Также проведен анализ и выявлены наиболее перспективные направления исследований как на животных, так и у человека.

Цель. Проанализировать опыт применения терапевтических средств при аппаратной перфузии донорских органов.

Материал и методы. Источники с 2015 по 2023 год, найденные в PubMed, Google Scholar, eLibrary.

Заключение. Стремительный прогресс в трансплантации легких, печени и почек позволил использовать трансплантаты от асистолических доноров для пациентов, остро нуждающихся в органах. В свою очередь, эти достижения также подтолкнули к изучению потенциальных терапевтических средств, которые могут быть использованы во время перфузии.

1. Готье С.В., Хомяков С.М. Донорство и трансплантация органов в Российской Федерации в 2021 году. XIV сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2022;24(3):8–31. https://doi.org/10.15825/1995-1191-2022-3-8-31

2. Busquets J, Xiol X, Figueras J, Jaurrieta E, Torras J, Ramos E, et al. The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation. 2001;71(12):1765–1771. PMID: 11455256 https://doi.org/10.1097/00007890-200106270-00011

3. Kawut SM, Reyentovich A, Wilt JS, Anzeck R, Lederer DJ, O'Shea MK, et al. Outcomes of extended donor lung recipients after lung transplantation. Transplantation. 2005;79(3):310–316. PMID: 15699761 https://doi.org/10.1097/01.tp.0000149504.53710.ae

4. Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515(7527):431–435. PMID: 25383517 https://doi.org/10.1038/nature13909

5. Petrenko A, Carnevale M, Somov A, Osorio J, Rodríguez J, Guibert E, et al. Organ preservation into the 2020s: the era of dynamic intervention. Transfus Med Hemother. 2019;46(3):151–172. PMID: 31244584 https://doi.org/10.1159/000499610

6. Rojas-Pena A, Bartlett RH. Ex situ organ preservation: the temperature paradigm. Transplantation. 2018;102(4):554–556. PMID: 29309378 https://doi.org/10.1097/TP.0000000000002081

7. Mordant P, Nakajima D, Kalaf R, Iskender I, Maahs L, Behrens P, et al. Mesenchymal stem cell treatment is associated with decreased perfusate concentration ofinterleukin-8 during ex vivo perfusion of donor lungs after 18-hourpreservation. J Heart Lung Transplant. 2016;35(10):1245–1254. PMID: 27444694 https://doi.org/10.1016/j.healun.2016.04.017

8. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA. 2009;106(38):16357–16362. https://doi.org/10.1073/pnas.0907996106

9. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med. 2013;187(7):751–760. PMID: 23292883 https://doi.org/10.1164/rccm.201206-0990OC

10. McAuley DF, Curley GF, Hamid UI, Laffey JG, Abbott J, McKenna DH, et al. Clinical grade allogeneic human mesen chymal stem cells restore alveolar fluid clearance inhuman lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol. 2014;306(9):L809– L815. PMID: 24532289 https://doi.org/10.1152/ajplung.00358.2013

11. Stone ML, Zhao Y, Robert Smith J, Weiss ML, Kron IL, Laubach VE, et al. Mesenchymal stromal cell-derived extracellular vesicles attenuate lung ischemiareperfusion injury and enhance reconditioning of donor lungs after circulatory death. Respir Res. 2017;18(1):212. PMID: 29268735 https://doi.org/10.1186/s12931-017-0704-9

12. Gennai S, Monsel A, Hao Q, Park J, Matthay MA, Lee JW. Microvesicles derived from human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Transplant. 2015;15(9):2404– 2412. PMID: 25847030 https://doi.org/10.1111/ajt.13271

13. Park J, Kim S, Lim H, Liu A, Hu S, Lee J, et al. Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia. Thorax. 2019;74(1):43–50. PMID: 30076187 https://doi.org/10.1136/thoraxjnl-2018-211576

14. Martens A, Ordies S, Vanaudenaerde BM, Verleden SE, Vos R, Van Raemdonck DE, et al. Immunoregulatory effects of multipotent adult progenitor cells in a porcine ex vivo lung perfusion model. Stem Cell Res Ther. 2017;8(1):159. PMID: 28676074 https://doi.org/10.1186/s13287-017-0603-5

15. La Francesca S, Ting AE, Sakamoto J, Rhudy J, Bonenfant NR, Borg ZD, et al. Multipotent adult progenitor cells decrease cold ischemic injury in ex vivo perfused human lungs: an initial pilot and feasibility study. Transplant Res. 2014;3(1):19. PMID: 25671090 https://doi.org/10.1186/2047-1440-3-19eCollection 2014.

16. Stone ML, Sharma AK, Mas VR, Gehrau RC, Mulloy DP, Zhao Y, et al. Ex vivo perfusion with adenosine A2A receptor agonist enhances rehabilitation of murine donor lungs after circulatory death. Transplantation. 2015;99(12):2494–2503. PMID: 26262504 https://doi.org/10.1097/TP.0000000000000830

17. Emaminia A, Lapar DJ, Zhao Y, Steidle JF, Harris DA, Laubach VE, et al. Adenosine A2A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg. 2011;92(5):1840–1846. PMID: 22051279 https://doi.org/10.1016/j.athoracsur.2011.06.062

18. Wagner CE, Pope NH, Charles EJ, Huerter ME, Sharma AK, Salmon MD, et al. Ex vivo lung perfusion with adenosine A2A receptor agonist allows prolonged cold preservation of lungs donated after cardiac death. J Thorac Cardiovasc Surg. 2016;151(2):538–545. PMID: 26323621 https://doi.org/10.1016/j.jtcvs.2015.07.075

19. Huerter ME, Charles EJ, Downs EA, Hu Y, Lau CL, Isbell JM, et al. Enteral access is not required for esophageal cancer patients undergoing neoadjuvant therapy. Ann Thorac Surg. 2016;102(3):948–954. PMID: 27209608 https://doi.org/10.1016/j.athoracsur.2016.03.041

20. Charles EJ, Kron IL. Which ischemic mitral valves should be repaired and how? Time will tell. J Thorac Cardiovasc Surg. 2017;154(3):833. PMID: 28826152 https://doi.org/10.1016/j.jtcvs.2017.05.006

21. Valenza F, Rosso L, Coppola S, Froio S, Colombo J, Dossi R, et al. β-adrenergic agonist infusion during extracorporeal lung perfusion: effects on glucose concentration in the perfusion fluid and on lung function. J Heart Lung Transplant. 2012;31(5):524–530. PMID: 22386450 https://doi.org/10.1016/jhealun.2012.02.001

22. Kondo T, Chen F, Ohsumi A, Hijiy a K, Motoyama H, Sowa T, et al. β2-adrenoreceptor agonist inhalation during ex vivo lung perfusion attenuates lung injury. Ann Thorac Surg. 2015;100(2):480–486. PMID: 26141779 https://doi.org/10.1016/j.athoracsur.2015.02.136

23. Hijiya K, Chen-Yoshikawa TF, Kondo T, Motoyama H, Ohsumi A, Nakajima D, et al. Bronchodilator inhalation during ex vivo lung perfusion improves posttransplant graft function after warm ischemia. Ann Thorac Surg. 2017;103(2):447–453. PMID: 27737734 https://doi.org/10.1016/j.athoracsur.2016.07.066

24. Inci I, Zhai W, Arni S, Inci D, Hillinger S, Lardinois D, et al. Fibrinolytic treatment improves the quality of lungs retrieved from non-heart-beating donors. J Heart Lung Transplant. 2007;26(10):1054–1060. PMID: 17919627 https://doi.org/10.1016/j.healun.2007.07.033

25. Nakajima D, Cypel M, Bonato R, Machuca TN, Iskender I, Hashimoto K, et al. Ex vivo perfusion treatment of infection in human donor lungs. Am J Transplant. 2016;16(4):1229–1237. PMID: 26730551 https://doi.org/10.1111/ajt.13562

26. Chen F, Nakamura T, Fujinaga T, Zhang J, Hamakawa H, Omasa M, et al. Protective effect of a nebulized beta2-adrenoreceptor agonist in warm ischemic-reperfused rat lungs. Ann Thorac Surg. 2006;82(2):465–471. PMID: 16863745 https://doi.org/10.1016/j.athoracsur.2006.01.010

27. Sakamoto J, Chen F, Nakajima D, Yamada T, Ohsumi A, Zhao X, et al. The effect of β-2 adrenoreceptor agonist inhalation on lungs donated after cardiac death in a canine lung transplantation model. J Heart Lung Transplant. 2012;31(7):773–779. PMID: 22534458 https://doi.org/10.1016/j.healun.2012.03.012

28. Machuca TN, Cypel M, Bonato R, Yeung JC, Chun YM, Juvet S, et al. Safety and efficacy of ex vivo donor lung adenoviral IL-10 gene therapy in a large animal lung transplant survival model. Hum Gene Ther. 2017;28(9):757– 765. PMID: 28052693 https://doi.org/10.1089/hum.2016.070

29. Andreasson A, Karamanou DM, Perry JD, Perry A, Ӧzalp F, Butt T, et al. The effect of ex vivo lung perfusion on microbial load in human donor lungs. J Heart Lung Transplant. 2014;33(9):910–916. PMID: 24631044 https://doi.org/10.1016/j.healun.2013.12.023

30. Galasso M, Feld JJ, Watanabe Y, Pipkin M, Summers C, Ali A, et al. Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. Nat Commun. 2019;10(1):481. PMID: 30696822 https://doi.org/10.1038/s41467-018-08261-z

31. Cypel M, Liu M, Rubacha M, Yeung JC, Hirayama S, Anraku M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009;1(4):4ra9. PMID: 20368171 https://doi.org/10.1126/scitranslmed.3000266

32. Yeung JC, Wagnetz D, Cypel M, Rubacha M, Koike T, Chun YM, et al. Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig. Mol Ther. 2012;20(6):1204–1211. PMID: 22453765 https://doi.org/10.1038/mt.2012.57

33. Figueiredo C, Carvalho Oliveira M, Chen-Wacker C, Jansson K, Höffler K, Yuzefovych Y, et al. Immunoengineering of the vascular endothelium to silence MHC expression during normothermic ex vivo lung perfusion. Hum Gene Ther. 2019;30(4):485–496. PMID: 30261752 https://doi.org/10.1089/hum.2018.117

34. McAuley DF, Frank JA, Fang X, Matthay MA. Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med. 2004;32(7):1470–1476. PMID: 15241090 https://doi.org/10.1097/01.ccm.0000129489.34416.0e

35. Machuca TN, Hsin MK, Ott HC, Chen M, Hwang DM, Cypel M, et al. Injury-specific ex vivo treatment of the donor lung: pulmonary thrombolysis followed by successful lung transplantation. Am J Respir Crit Care Med. 2013;188(7):878–880. PMID: 24083866 https://doi.org/10.1164/rccm.2013020368LE

36. Jamieson RW, Zilvetti M, Roy D, Hughes D, Morovat A, Coussios CC, et al. Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model. Transplantation. 2011;92(3):289–295. PMID: 21681143 https://doi.org/10.1097/TP.0b013e318223d817

37. Liu Q, Berendsen T, Izamis ML, Uygun B, Yarmush ML, Uygun K. Perfusion defatting at subnormothermic temperatures in steatotic rat livers. Transplant Proc. 2013;45(9):3209–3213. PMID: 24182786 https://doi.org/10.1016/j.transproceed.2013.05.005

38. Nagrath D, Xu H, Tanimura Y, Zuo R, Berthiaume F, Avila M, et al. Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. Metab Eng. 2009;11(4–5):274–283. PMID: 19508897 https://doi.org/10.1016/j.ymben.2009.05.005

39. Hara Y, Akamatsu Y, Maida K, Kashiwadate T, Kobayashi Y, Ohuchi N, et al. A new liver graft preparation method for uncontrolled non-heart-beating donors, combining short oxygenated warm perfusion and prostaglandin E1. J Surg Res. 2013;184(2):1134–1142. PMID: 23688794 https://doi.org/10.1016/j.jss.2013.04.030

40. Maida K, Akamatsu Y, Hara Y, Tokodai K, Miyagi S, Kashiwadate T, et al. Short oxygenated warm perfusion with prostaglandin E1 administration before cold preservationas a novel resuscitation method for liver grafts from donors after cardiac death in a rat in vivo model. Transplantation. 2016;100(5):1052– 1058. PMID: 26950723 https://doi.org/10.1097/TP.0000000000001127

41. Nassar A, Liu Q, Farias K, D'Amico G, Buccini L, Urcuyo D, et al. Role of vasodilation during normothermic machine perfusion of DCD porcine livers. Int J Artif Organs. 2014;37(2):165–172. PMID: 24619899 https://doi.org/10.5301/ijao.5000297

42. Echeverri J, Goldaracena N, Kaths JM, Linares I, Roizales R, Kollmann D, et al. Comparison of BQ123, epoprostenol, and verapamil as vasodilators during normothermic ex vivo liver machine perfusion. Transplantation. 2018;102(4):601–608. PMID: 29189484 https://doi.org/10.1097/TP.0000000000002021

43. Goldaracena N, Spetzler VN, Echeverri J, Kaths JM, Cherepanov V, Persson R, et al. Inducing hepatitis C virus resistance after pig liver transplantationa proof of concept of liver graft modification using warm ex vivo perfusion. Am J Transplant. 2017;17(4):970–978. PMID: 27805315 https://doi.org/10.1111/ajt.14100

44. Gillooly AR, Perry J, Martins PN. First report of siRNA uptake (forRNA interference) during ex vivo hypothermic and normothermic liver machine perfusion. Transplantation. 2019;103(3):e56–e57. PMID: 30418428 https://doi.org/10.1097/TP.0000000000002515

45. Thijssen MF, Brüggenwirth IMA, Gillooly A, Khvorova A, Kowalik TF, Martins PN. Gene silencing with siRNA (RNA interference): a new therapeutic option during ex vivo machine liver perfusion preservation. Liver Transpl. 2019;25(1):140–151. PMID: 30561891 https://doi.org/10.1002/lt.25383

46. Goldaracena N, Echeverri J, Spetzler VN, Kaths JM, Barbas AS, Louis KS, et al. Anti-inflammatory signaling during ex vivo liver perfusion improves the preservation of pig liver grafts before transplantation. Liver Transpl. 2016;22(11):1573–1583. PMID: 27556578 https://doi.org/10.1002/lt.24603

47. Rigo F, De Stefano N, NavarroTableros V, David E, Rizza G, Catalano G, et al. Extracellular vesicles from human liver stem cells reduce injury in an ex vivo normothermic hypoxic rat liver perfusion model. Transplantation. 2018;102(5):e205–e210. PMID: 29424767 https://doi.org/10.1097/TP.0000000000002123

48. Beal EW, Kim JL, Reader BF, Akateh C, Maynard K, Washburn WK, et al. [D-Ala2, D-Leu5] Enkephalin improves liver preservation during normothermic ex vivo perfusion. J Surg Res. 2019;241:323–335. PMID: 31071481 https://doi.org/10.1016/j.jss.2019.04.010

49. Yu Y, Cheng Y, Pan Q, Zhang YJ, Jia DG, Liu YF. Effect of the selective NLRP3 inflammasome inhibitor mcc950 on transplantation outcome in a pig liver transplantation model with organs from donors after circulatory death preserved by hypothermic machine perfusion. Transplantation. 2019;103(2):353– 362. PMID: 30247318 https://doi.org/10.1097/TP.0000000000002461

50. Yang B, Hosgood SA, Bagul A, Waller HL, Nicholson ML. Erythropoietin regulates apoptosis, inflammation and tissue remodelling via caspase-3 and IL-1β in isolated hemoperfused kidneys. Eur J Pharmacol. 2011;660(23):420–430. PMID: 21497595 https://doi.org/10.1016/j.ejphar.2011.03.044

51. Yang C, Hosgood SA, Meeta P, Long Y, Zhu T, Nicholson ML, et al. Cyclic helix B peptide inpreservation solution and autologous blood perfusate ameliorates ischemia-reperfusion injury in isolated porcine kidneys. Transplant Direct. 2015;1(2):e6. PMID: 27500213 https://doi.org/10.1097/TXD.0000000000000515

52. Tietjen GT, Hosgood SA, DiRito J, Cui J, Deep D, Song E, et al. Nanoparticle targeting to then do the lium during normothermic machine perfusion of human kidneys. Sci Transl Med. 2017;9(418):eaam6764. PMID: 29187644 https://doi.org/10.1126/scitranslmed.aam6764

53. Pool M, Eertman T, Sierra Parraga J, 't Hart N, Roemeling-van Rhijn M, Eijken M, et al. Infusing mesenchymal stromal cells into porcine kidneys during normothermic machine perfusion: intact MSCs can be traced and localised to glomeruli. Int J Mol Sci. 2019;20(14):3607. PMID: 31340593 https://doi.org/10.3390/ijms20143607

54. Brasile L, Henry N, Orlando G, Stubenitsky B. Potentiating renal regeneration using mesenchymal stem cells. Transplantation. 2019;103(2):307–313. PMID: 30234788 https://doi.org/10.1097/TP.0000000000002455

55. Hamaoui K, Gowers S, Boutelle M, Cook TH, Hanna G, Darzi A, et al. Organ pretreatment withcytotopic endothelial localizing peptides to ameliorate microvascular thrombosis and perfusion deficits in ex vivo renal hemoreperfusion models. Transplantation. 2016;100(12):e128–e139. PMID: 27861293 https://doi.org/10.1097/TP.0000000000001437

56. Gregorini M, Corradetti V, Pattonieri EF, Rocca C, Milanesi S, Peloso A, et al. Perfusion of isolated rat kidney with mesenchymal stromal cells/extracellular vesicles prevents ischaemic injury. J Cell Mol Med. 2017;21(12):3381–3393. PMID: 28639291 https://doi.org/10.1111/jcmm.13249

57. Bhattacharjee RN, Richard-Mohamed M, Sun Q, Haig A, Aboalsamh G, Barrett P, et al. CORM-401 reduces ischemia reperfusion injury in an ex vivo renal porcine model of the donation after circulatory death. Transplantation. 2018;102(7):1066–1074. PMID: 29677080 https://doi.org/10.1097/TP.0000000000002201

58. Sedigh A, Nordling S, Carlsson F, Larsson E, Norlin B, Lübenow N, et al. Perfusion of porcine kidneys with macromolecular heparin reduces early ischemia reperfusion injury. Transplantation. 2019;103(2):420–427. PMID: 30299374 https://doi.org/10.1097/TP.0000000000002469

59. Sierra Parraga JM Rozenberg K, Eijken M, Leuvenink HG, Hunter J, Merino A, et al. Effects of normothermic machine perfusion conditions on mesenchymal stromal cells. Front Immunol. 2019;10:765. PMID: 31024574 https://doi.org/10.3389/fimmu.2019.00765eCollection 2019